These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216 [TBL] [Abstract][Full Text] [Related]
5. Dose selection and comparator drugs in schizophrenia research. Kane JM J Clin Psychiatry; 2001; 62 Suppl 9():29-32; discussion 33-4. PubMed ID: 11379828 [TBL] [Abstract][Full Text] [Related]
6. Evaluating characteristics of patient selection and dropout rates. Keith SJ J Clin Psychiatry; 2001; 62 Suppl 9():11-4; discussion 15-6. PubMed ID: 11379825 [TBL] [Abstract][Full Text] [Related]
7. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Woods SW; Gueorguieva RV; Baker CB; Makuch RW Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728 [TBL] [Abstract][Full Text] [Related]
8. Selection of atypical antipsychotics for the management of schizophrenia. Sprague DA; Loewen PS; Raymond CB Ann Pharmacother; 2004 Feb; 38(2):313-9. PubMed ID: 14742771 [TBL] [Abstract][Full Text] [Related]
9. Clinical development of atypical antipsychotics: research design and evaluation. Collaborative Working Group on Clinical Trial Evaluations. J Clin Psychiatry; 1998; 59 Suppl 12():10-6. PubMed ID: 9766614 [TBL] [Abstract][Full Text] [Related]
10. Overview of the findings from the European SOHO study. Suarez D; Haro JM Expert Rev Neurother; 2008 Jun; 8(6):873-80. PubMed ID: 18505352 [TBL] [Abstract][Full Text] [Related]
11. Enhancing the validity and utility of randomized clinical trials in addictions treatment research: II. Participant samples and assessment. Del Boca FK; Darkes J Addiction; 2007 Aug; 102(8):1194-203. PubMed ID: 17511752 [TBL] [Abstract][Full Text] [Related]
12. Introduction: evaluating clinical trial data from schizophrenia research. Tamminga CA J Clin Psychiatry; 2001; 62 Suppl 9():3-4. PubMed ID: 11379829 [No Abstract] [Full Text] [Related]
14. A review of the limitations of statistical analysis of treatment outcomes used in periodontal research. Galgut PN J Int Acad Periodontol; 2003 Oct; 5(4):92-7. PubMed ID: 14604057 [TBL] [Abstract][Full Text] [Related]
15. Placebo or active control trials of antipsychotic drugs? Fleischhacker WW; Czobor P; Hummer M; Kemmler G; Kohnen R; Volavka J Arch Gen Psychiatry; 2003 May; 60(5):458-64. PubMed ID: 12742866 [TBL] [Abstract][Full Text] [Related]
16. Efficacy endpoint selection and multiplicity adjustment methods in clinical trials with inherent multiple endpoint issues. Sankoh AJ; D'Agostino RB; Huque MF Stat Med; 2003 Oct; 22(20):3133-50. PubMed ID: 14518019 [TBL] [Abstract][Full Text] [Related]
17. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718 [TBL] [Abstract][Full Text] [Related]